89288-22-2

Basic information

• Product Name: (S)-2-AMino-3-(4-nitrophenyl)propanol
• Synonyms: (S)-2-AMino-3-(4-nitrophenyl)propanol;(S)-b-AMino-4-nitrobenzenepropanol;(2S)-2-AMino-3-(4-nitrophenyl)-1-propanol;(2S)-2-amino-3-(4-nitrophenyl)propan-1-ol
• CAS NO: 89288-22-2
• Molecular Formula: C₉H₁₂N₂O₃
• Molecular Weight: 196.20318
• Mol File: 89288-22-2.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-2-AMino-3-(4-nitrophenyl)propanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-AMino-3-(4-nitrophenyl)propanol(89288-22-2)
• EPA Substance Registry System: (S)-2-AMino-3-(4-nitrophenyl)propanol(89288-22-2)

Safety Data

• Hazardous Substances Data: 89288-22-2(Hazardous Substances Data)

Usage

Uses

(2S)-2-Amino-3-(4-nitrophenyl)-1-propanol, can be used as an intermediate in the synthesis of various pharmaceutical compounds. It is used in the preparation of a new series of 2-substituted thiazole carboxamides, as potent inhibitors of Akt kinases.

Upstream product

• 34276-53-4 ethyl (S)-2-amino-3-(4-nitrophenyl)propionate 
• 17193-40-7 (S)-4-nitrophenylalanine methyl ester hydrochloride 
• 114346-29-1 tert-butyl N-[(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]carbamate 
• 100616-58-8 (R or S)-1-acetoxy-2-acetylamino-3-(4-nitro-phenyl)-propane 
• 63-91-2 L-phenylalanine 
• 85317-52-8 methyl 2-amino-3-(4-nitrophenyl)propionate 
• 1991-83-9 4-nitrophenylalanine 
• 55895-91-5 ethyl 2-amino-3-(4-nitrophenyl) propanoate 
• 81677-60-3 (L)-p-Nitrophenylalanine methyl ester 
• 949-99-5 4-nitro-3-phenyl-L-alanine 
• 33305-77-0 Boc-Phe(p-NO₂)-OH 
• 65615-89-6 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-nitrophenyl)propanoate 
• 6265-86-7 formylamino-(4-nitro-benzyl)-malonic acid diethyl ester 

Downstream Products

• 139264-55-4 (S)-4-(4'-nitrobenzyl)-1,3-oxazolidin-2-one 
• 823797-88-2 (S)-2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-nitro-phenyl)-propan-1-ol 
• 726134-79-8 (S)-2-amino-3-(4-aminophenyl)propan-1-ol 
• 183669-13-8 tert-butyl (1-hydroxy-3-(4-nitrophenyl)propan-2-yl)carbamate 
• 388060-55-7 tert-butyl 2-{[2-(tert-butoxy)-2-oxoethyl]({1-hydroxy-3-[4-nitrophenyl]propan-2-yl})amino}acetate 
• 769969-25-7 (S)-tert-butyl 2-{[2-(tert-butoxy)-2-oxoethyl]({1-hydroxy-3-[4-nitrophenyl]propan-2-yl})amino}acetate 
• 1610608-12-2 (S)-3-((1S,2R)-1,2-diethyl-2-vinylcyclopropanecarbonyl)-4-(4-nitrobenzyl)oxazolidin-2-one 
• 1610608-07-5 (S)-3-((1R,2S)-1,2-diethyl-2-vinylcyclopropanecarbonyl)-4-(4-nitrobenzyl)oxazolidin-2-one 
• 1599422-74-8 tert-butyl 2-{[(2,4-dimethoxyphenyl)methyl][(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]amino}acetate 
• 1599422-73-7 tert-butyl 2-{(benzyl)[(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]-amino}acetate 
• 1599422-72-6 (2S)-2-{[(2,4-dimethoxyphenyl)methyl]amino}-3-(4-nitrophenyl)-propan-1-ol 
• 406164-95-2 (2S)-2-(benzylamino)-3-(4-nitrophenyl)propan-1-ol 
• 114346-29-1 tert-butyl N-[(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]carbamate 
• 1353022-71-5 N-[2-chloro-3-(4-nitrophenyl)propyl]-4-methylbenzene-1-sulfonamide 

Relevant articles and documents

Synthesis of Water-Soluble Chiral DOTA Lanthanide Complexes with Predominantly Twisted Square Antiprism Isomers and Circularly Polarized Luminescence

One-step cyclization of a tetraazamacrocycle 5 with 70% yield in a 25-g scale was performed. Its chiral DOTA derivatives, L4, has ?93% of TSAP coordination isomer in its Eu(III) and Yb(III) complexes in aqueous solution. [GdL4]5- exhibits a high relaxivity, making it a promising and efficient MRI contrast agent. High luminescence dissymmetry factor (glum) values of 0.285 (ΔJ = 1) for [TbL3]- and 0.241 (ΔJ = 1) for [TbL4]5- in buffer solutions were recorded.

COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

ANTIBODY DRUG CONJUGATES

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.